Pharma’s Dems Are Doing Trump’s Dirty Work On Drug Prices
As the first-ever Medicare drug-price negotiations take shape, Big Pharma-backed Democrats want to limit the number of costly medicines regulators can target.
Business
Critical coverage on the global financial system and domestic policies that shape the U.S. economy, with a focus on corporate wrongdoing.
Banks Want To Protect Their Junkiest Junk Fee
Banks are fighting a rule that would stop predatory fees they claim they don’t even charge.
The Killer-Sunshine State
A state effort to outlaw workplace heat-protection standards is a preview of what will happen as the GOP’s war on workers collides with our climate reality.
The Lie That’s Inflating Your Credit Card Bills
Credit card companies doubled interest rates on the false claim of inflated financial risk — and now to fight new late-fee rules, they’re threatening to raise them even higher.
The Plutocrats’ Plot To Control America
Under the banner of voting reform, a tycoon’s plan could give the rich even more power to buy elections.
YOU LOVE TO SEE IT: States Depoliticize Utility Bills
Plus, Oregon aims to limit corporate takeover of medical clinics, federal regulators investigate private use of corporate aircrafts, and more student debt relief is on the way.
The Fed Is Behind The Credit Card Merger
If Capital One is allowed to acquire Discover, it’ll gain access to a government loophole allowing it to raise prices and reduce competition.
Elon Musk Flees To Billionaires’ New Court
Burned by legal decisions, Elon Musk is relocating his rocket company to Texas — where he’ll enjoy a new, separate justice system controlled by his ally, Gov. Greg Abbott.
YOU LOVE TO SEE IT: Mega-Merger (Potentially) Blocked On Aisle Five
Plus, consumers could be protected from insurer meltdowns, dueling communities reach rare agreement over water rights, and rural America scores access to clean water.
Americans Paid $11 Billion To Make Drugs You Can’t Afford
A bombshell report reveals that taxpayers spent billions developing medicines that drugmakers say shouldn’t face Medicare price negotiations.